Eric Murphy, Alterome CEO
Mysterious OrbiMed-backed biotech nears $100M in funding, hints at plans to go after ‘undruggable 3.0’
In January, Alterome launched from stealth — but remained quite stealthy. While the biotech put out a press release for its $64 million Series A, led …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
